Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roxadustat and Entresto in Cardiorenal Anemia Syndrome
NCT05053893Unknown
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Sep 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of roxadustat and sacubitril + valsartan in Cardio-renal anemia syndrome (CRAS) (2 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoints: Change in hemoglobin at 90 days, Change in ejection fraction at 90 days and 1 more. Status: unknown.
02
Drugs
roxadustatsacubitril + valsartan
03
Conditions
Cardio-renal anemia syndrome (CRAS)
Beyond the preview
Go deeper on NCT05053893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05053893.